Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of Dasatinib (DAS) Vs. Imatinib (IM) by Baseline Comorbidity In Patients with Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of the DASISION Trial.

H. Jean Khoury, MD, FACP, Jorge E. Cortes, MD, Hagop Kantarjian, MD, Michele Baccarani, MD, Neil P. Shah, MD, Ph.D., M. Brigid Bradley-Garelik, MD, David Dejardin, Andreas Hochhaus, MD

Blood (2010) 116 (21): 3421.

https://doi.org/10.1182/blood.V116.21.3421.3421

Published: 2010

Journal Articles

Lymphocytosis Following First-Line Treatment for CML In Chronic Phase with Dasatinib Is Associated with Improved Responses: A Comparison with Imatinib

Charles A. Schiffer, Jorge E. Cortes, Giuseppe Saglio, Philipp le Coutre, Francois Guilhot, Erkut Bahceci, David Dejardin, Neil P. Shah

Blood (2010) 116 (21): 358.

https://doi.org/10.1182/blood.V116.21.358.358

Published: 2010

Journal Articles

Safety and Efficacy of Dasatinib Versus Imatinib by Baseline Cardiovascular Comorbidity In Patients with Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of the DASISION Trial

Giuseppe Saglio, MD, PhD, Andreas Hochhaus, MD, Ph.D., Jorge E. Cortes, MD, Hagop Kantarjian, MD, Michele Baccarani, MD, M. Brigid Bradley-Garelik, MD, David Dejardin, Neil P. Shah, MD, Ph.D.

Blood (2010) 116 (21): 2286.

https://doi.org/10.1182/blood.V116.21.2286.2286

Published: 2010

Journal Articles

Dasatinib (Versus Imatinib) In Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of Safety and Efficacy by Use of Baseline Medications In the DASISION Trial

Francois Guilhot, Hagop Kantarjian, MD, Neil P. Shah, Andreas Hochhaus, M. Brigid Bradley-Garelik, David Dejardin, Jorge E. Cortes, MD

Blood (2010) 116 (21): 2295.

https://doi.org/10.1182/blood.V116.21.2295.2295

Published: 2010

Journal Articles

Dasatinib or High-Dose Imatinib for Patients with Chronic-Phase Chronic Myeloid Leukemia Resistant to Standard-Dose Imatinib: 2-Year Follow-Up Data from START-R (CA180-017).

Hagop M. Kantarjian, MD, Philippe Rousselot, MD, Ricardo Pasquini, MD, Nelson Hamerschlak, MD, Jerzy Holowiecki, MD, David Dejardin, Eric Bleickardt, MD, Neil P. Shah, MD

Blood (2007) 110 (11): 736.

https://doi.org/10.1182/blood.V110.11.736.736

Published: 2007

NARROW

Safety and Efficacy of Dasatinib (DAS) Vs. Imatinib (IM) by Baseline Comorbidity In Patients with Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of the DASISION Trial.

Lymphocytosis Following First-Line Treatment for CML In Chronic Phase with Dasatinib Is Associated with Improved Responses: A Comparison with Imatinib

Safety and Efficacy of Dasatinib Versus Imatinib by Baseline Cardiovascular Comorbidity In Patients with Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of the DASISION Trial

Dasatinib (Versus Imatinib) In Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of Safety and Efficacy by Use of Baseline Medications In the DASISION Trial

Dasatinib or High-Dose Imatinib for Patients with Chronic-Phase Chronic Myeloid Leukemia Resistant to Standard-Dose Imatinib: 2-Year Follow-Up Data from START-R (CA180-017).

Email alerts

ASH Publications

American Society of Hematology

Safety and Efficacy of Dasatinib (DAS) Vs. Imatinib (IM) by Baseline Comorbidity In Patients with Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of the DASISION Trial.

Lymphocytosis Following First-Line Treatment for CML In Chronic Phase with Dasatinib Is Associated with Improved Responses: A Comparison with Imatinib

Safety and Efficacy of Dasatinib Versus Imatinib by Baseline Cardiovascular Comorbidity In Patients with Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of the DASISION Trial

Dasatinib (Versus Imatinib) In Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of Safety and Efficacy by Use of Baseline Medications In the DASISION Trial

Dasatinib or High-Dose Imatinib for Patients with Chronic-Phase Chronic Myeloid Leukemia Resistant to Standard-Dose Imatinib: 2-Year Follow-Up Data from START-R (CA180-017).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only